Disclosures for "Healthcare Providers’ Practice and Perception on Discussing Life Expectancy with Duchenne Patients and Caregivers: A Mixed Quantitative/Qualitative Survey"
-
Mr. Copeland has nothing to disclose.
-
Dr. Treat has nothing to disclose.
-
Miss Wagner has received personal compensation for serving as an employee of Parent Project Muscular Dystrophy.
-
Mrs. Schrader has nothing to disclose.
-
Dr. Veerapandiyan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AMO Pharma, AveXis, Biogen, Edgewise Therapeutics, FibroGen, Novartis, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Inc., UCB Pharma, Catalyst, Entrada, Scholar Rock, Catalyst, Lupin. Dr. Veerapandiyan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. The institution of Dr. Veerapandiyan has received research support from AMO Pharma, Capricor Therapeutics, Edgewise Therapeutics, FibroGen, Muscular Dystrophy Association, Novartis, Parent Project Muscular Dystrophy, Pfizer, RegenxBio and Sarepta Therapeutics. Dr. Veerapandiyan has received personal compensation in the range of $5,000-$9,999 for serving as a MD with PPMD, MDA.